The purpose of this TriMark Publications report is to describe the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing. This study examines clinical measurement devices and their reagents and supplies as used in hospitals, clinics and doctorâ€™s offices. This examination is arranged to provide the reader with an overview of the outstanding diagnostic test market segments of cardiac care, with evidence that these segments are poised for high future growth. An overview of the diagnostic testing cardiac marker market is presented with the latest information regarding emerging new products and industry trends. It will not only quantify but also qualify the cardiac marker market segments as an area of research, product development and investment. Forecasts of the cardiac marker market and an analysis of products in the worldwide diagnostics market will provide a basis for understanding the significance of past developments and future possibilities within this diagnostic category.
Table of Contents : 1. Overview 1.1 Statement of Report 1.2 Objectives of This Report 1.3 Scope of This Report 1.4 Methodology 1.5 Executive Summary 2. Introduction 2.1 Global Diagnostic Products Industry 2.2 Barriers to Entry 2.3 Company Evaluation Overview 2.4 Market Outlook 2.5 Technologies and Products that are the Most Successful in the New IVD Environment 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 3.1 Global Cardiac Marker Diagnostic Testing Markets 3.1.1 Clinical Utility of Cardiac Markers 3.1.2 Market Drivers in the Cardiac Marker Diagnostics Testing Sector 3.1.3 Market Restraints in Cardiac Marker Testing Segment 3.1.4 Principal Market Segments for Cardiac Marker Testing 3.1.5 Key Players in the Cardiac Marker Diagnostics Testing Segment 3.1.6 Cardiac Marker Testing Sector Analysis 3.1.7 Cardiac Marker Market Share 3.2 U.S. Cardiac Marker Testing Market 3.2.1 Market Overview 3.2.2 Diagnostic Test Categories 3.2.3 U.S. Hospital POC Cardiac Markers 3.3 European Cardiac Marker Diagnostic Test Market 3.3.1 German Diagnostic Markets 3.3.2 U.K. Diagnostic Testing Market 188.8.131.52 U.K. Market Statistics 184.108.40.206 U.K. Competitive Analysis 220.127.116.11 U.K. Market Access 3.3.3 Italy 3.3.4 France 3.3.5 Spain 3.3.6 Belgium 3.3.7 Switzerland 3.3.8 Barriers to Entry to European Market 3.4 Japanese Diagnostic Testing Market 3.5 Chinese Diagnostic Testing Market 3.6 Canadian Diagnostic Market 3.7 Cardiac Marker Testing Individual Markets 3.7.1 Clinical Overview 3.7.2 Cardiac Acute Disease Markers 3.7.3 Market Overview 18.104.22.168 AMI and Troponins 22.214.171.124 Market Size and Growth Projections 126.96.36.199 Clinical Use of Cardiac Troponins 188.8.131.52 TnI and TnT Market Drivers 184.108.40.206 TnI and TnT Market Restraints 220.127.116.11 New Tests for Troponin 3.7.4 CK-MB and Cardiac Enzymes 18.104.22.168 CK Enzymes 22.214.171.124 Market Size and Growth Projections 126.96.36.199 CK-MB: Market Drivers 188.8.131.52 CK-MB: Market Restraints 3.7.5 Myoglobin 184.108.40.206 Market Size and Growth Projections 220.127.116.11 Clinical Use of Myoglobin 18.104.22.168 Myoglobin Market Drivers 22.214.171.124 Myoglobin Market Restraints 3.7.6 BNP 126.96.36.199 Market Overview 188.8.131.52 Market Size and Growth Projections 184.108.40.206 Commercial Assays for BNP and NT-proBNP 220.127.116.11 Competitive Landscape 18.104.22.168 BNP Test Market Share 22.214.171.124 Clinical Applications of BNP 126.96.36.199 BNP Market Drivers 188.8.131.52 BNP Market Restraints 3.7.7 Albumin 184.108.40.206 Intact Albumin 220.127.116.11 Albumin Cobalt Binding Test 18.104.22.168 Ischemic Modified Albumin 22.214.171.124 Microalbuminuria 3.7.8 Key Players in Cardiac Markers 3.7.9 Cardiac Marker Controls 3.7.10 Evaluation of Cardiac Markers 3.7.11 Cardiac Markers Use in Clinical Decisions 3.7.12 Status of Cardiac Markers in the ER 3.7.13 Cardiac Markers in Renal Failure 3.7.14 Troponins in Non-Ischemic Heart Disease 3.7.15 Market Restraints 3.7.16 Market Drivers 3.7.17 Cardiac Panels 3.7.18 POC Cardiac Markers 126.96.36.199 Market Size and Growth Rate 188.8.131.52 Market Restraints 184.108.40.206 The Next Wave 4. Cardiovascular Disease Markers 4.1 Cholesterol, HDL and LDL 4.1.1 Cholesterol Testing Market Forecasts 4.1.2 Cholesterol Market Growth Drivers 4.1.3 Market Outlook: U.S. Market Analysis 4.1.4 Trends and Issues 4.1.5 Key Players in the Cholesterol OTC Kit Market 4.2 Homocysteine 4.3 Fibrinogen 4.4 C-Reactive Protein 4.5 Lipoprotein Fractions 4.6 Pulmonary Embolism (D-Dimer Test) 4.7 Oxidized LDL and HDL 4.8 Stroke 5. Cardiac Marker Testing Development Issues 5.1 Genetic Testing and Personalized Medicine 5.2 Preventive Medicine 5.3 Patient Safety and Quality Measures 5.4 Reimbursement 5.5 Cardiovascular 5.6 Screening for Diabetes 5.7 Other Reimbursement Concerns 5.7.1 Reimbursement for Routine Venipuncture 5.7.2 Japanese Reimbursements for Medical Devices 5.8 CPT Test Codes and Payment Amounts 5.9 Rapid Near-Patient Testing in Hospitals 5.10 Satellite Facilities 5.11 Regionalization of Laboratory Care 5.12 Requirements for POCT 5.12.1 Benefits of POCT 5.12.2 Turnaround Time for POCT 5.13 Clinical Laboratory Improvement Amendments (CLIA) 5.14 Quality Assurance Issues 5.15 Political Control 5.16 Regulatory Requirements 5.17 Recordkeeping and Data Management 5.17.1 Effectiveness of Clinical Outcomes
LIST OF FIGURES Figure 2.1: Lab Industry Market Share Figure 2.2: Market Share of Major Lab Testing Segments
LIST OF TABLES Table 2.1: World Population and Growth, 2000-2024 Table 2.2: Worldwide Market Share IVD Companies Table 2.3: U.S. In Vitro Central Lab Diagnostic Testing, 2001-2007 Table 2.4: Worldwide Near-Patient Diagnostic Testing, 2001-2007 Table 3.1: Cardiac Marker Markets by Country, 2002-2010 Table 3.2: Total Global Cardiac Marker Market, 2002-2010 Table 3.3: Overall IVD Testing Market Worldwide, 2007 Table 3.4: Worldwide Distribution of IVD Testing, 2007 Table 3.5: Top 12 Countries for IVD Testing Markets, 2007 Table 3.6: Eight Largest Diagnostic Companies Worldwide, 2007 Table 3.7: Cardiac Markers Table 3.8: Market Share of Cardiac Marker Segment Table 3.9: U.S. Cardiac Marker Market, 2001-2010 Table 3.10: U.S. Cardiac Marker Diagnostic Testing Market Segments, 2007 Table 3.11: U.S. POC Cardiac Marker Sales, 2001-2010 Table 3.12: The Cardiac Marker Market for Diagnostic Testing in Europe, 2001-2010 Table 3.13: Regional Comparison of Healthcare and IVD Expenditures Table 3.14: German Diagnostics Products Market Sales, 1997-2008 Table 3.15: The German Cardiac Marker Test Market, 2000-2010 Table 3.16: U.K. Cardiac Marker Market, 2001-2010 Table 3.17: Major U.K. IVD Manufacturers Table 3.18: U.S. IVD Manufacturers Doing Business in the U.K. Table 3.19: Other European Companies that Manufacture IVD Products in the U.K. Table 3.20: Italian Cardiac Marker Market, 2001-2010 Table 3.21: French Cardiac Marker Market, 2001-2010 Table 3.22: Spanish Cardiac Marker Market, 2001-2010 Table 3.23: Japanese Cardiac Marker Diagnostic Testing Market, 2001-2010 Table 3.24: Chinese Diagnostics Products Market, 2000-2010 Table 3.25: ER Admissions in the U.S., 1997-2005 Table 3.26: Common Causes of Chest Pain Table 3.27: Rate of Inappropriate Discharge from the ER for Patients with AMI Table 3.28: Continuing Analytical Issues for Implementation of Cardiac Troponin Table 3.29: Global Cardiac Troponin Marker Market, 2001-2010 Table 3.30: U.S. Cardiac Troponin Marker Market, 2001-2010 Table 3.31: Trends in U.S. Sales of POC Cardiac Marker Tests, 1998-2007 Table 3.32: World Revenue from CK-MB Markets, 2001-2010 Table 3.33: U.S. Revenue from CK-MB Markets, 2001-2010 Table 3.34: World Myoglobin Market Revenues, 2001-2010 Table 3.35: U.S. Myoglobin Market Revenues, 2001-2010 Table 3.36: BNP Clinical Characteristics Table 3.37: Worldwide Sales of BNP Diagnostic Tests, 2004-2010 Table 3.38: U.S. Sales of BNP Diagnostic Tests, 2004-2010 Table 3.39: Commercial BNP Assays in the U.S. Table 3.40: Market Share of BNP Assays in the U.S. Table 3.41: Market Share of NT-proBNP Assays in the U.S. Table 3.42: Siemens Healthcare Diagnostics Cardiac Marker Assays Table 3.43: Cardiac Markers: Sampling Frequency Table 3.44: Cardiac Marker Products by LifeSign